Skip To The Main Content
About OREF


DePuy Synthes Investigator Initiated Study (IIS) Portal

DePuy Synthes supports unique, non-duplicative, independent clinical research studies of scientific and business merit with grants providing either funding and/or product(s). The IIS program mission is to encourage investigators to pursue and publish original research in areas relevant to the company’s business. Results of these studies are usually published in peer-reviewed medical journals and/or presented at local and global medical congresses, to share knowledge with the entire medical community.

To begin the process of submitting a proposal, click on the link below to go to the portal. Note: you will be leaving the OREF website and will be subject to DePuy Synthes' privacy policy and terms of use. 

Investigator Initiated Study Portal (IIS) DePuy Synthes

Supporting Your Subspecialty

OREF is proud to fund high quality research across all subspecialties as illustrated by the chart below showing funding from 2013-2017, including more than $2.3 million in 2017 for research in areas such as regenerative medicine and cellular therapies, oncology and patient safety.

OREF 2013-2017 Grant Funding by Topic

Study Examines Impact of OREF Grants on NIH Funding

A study recently published in the Journal of Bone and Joint Surgery (JBJS) analyzed the rate at which investigators receiving certain OREF grants were able to secure funding from the National Institutes of Health (NIH) after receiving their OREF grant. The study compared the future funding success of NIH applicants who received OREF funding and those who did not. Additionally, the authors analyzed OREF data about all grant programs between 1994 and 2014 for the purposes of determining whether or not there was a positive correlation between receiving any OREF grant and subsequent NIH funding.

Selected highlights from the analysis are presented below. The article is available here. (You must have a subscription to access the complete article, or pay for one-time access.)

OREF grant recipients subsequently receiving NIH funding also varied by OREF study type:

  • Basic – cell (n=21 or 35% vs 39 or 65% who did not receive NIH)
  • Basic – biomechanical (n=5 or 33% vs 10 or 67% who did not receive NIH)
  • Clinical (n=3 or 4% vs 43 or 96% who did not receive NIH)
  • Epidemiology (n=2 or 38% vs 8 or 62% who did not receive NIH)

Researchers from certain subspecialties are more likely to get both OREF and NIH funding. Sports medicine had the highest number of NIH grant winners, but Pediatrics had a higher proportion of NIH winners. The list below shows the number of OREF and NIH grants by subspecialty.

  • Arthroplasty: 25 OREF - 5 NIH
  • Sports Medicine: 18 OREF - 6 NIH
  • Oncology: 18 OREF - 5 NIH
  • Trauma: 17 OREF - 2 NIH
  • Pediatrics: 10 OREF - 5 NIH
  • Hand: 8 OREF - 2 NIH
  • Shoulder/Elbow: 8 OREF - 2 NIH
  • Foot/Ankle: 6 OREF - 2 NIH

Average H index at time of receiving an OREF grant was significantly higher for those who ultimately received NIH funding than those researchers who did not:

  • Avg H index at OREF who receive NIH = 15.29
  • Avg H index at OREF who do NOT receive NIH = 9.3

The average time from 1st publication to OREF grant was longer for NIH awardees than non-NIH awardees:

  • NIH funded: Average time from 1st publication to OREF grant: 12.16 years
  • Non-NIH funded: Average time from 1st publication to OREF grant: 8.26 years

4th edition of USBJI's "The Burden of Musculoskeletal Disease in the United States" now available.

The United States Bone and Joint Initiative (USBJI) released the 4th edition of its landmark analysis of the impact of musculoskeletal disease in the United States. The comprehensive report examines the physical and economic cost of musculoskeletal disease and injury and is widely referenced by individuals and institutions engaged in research, education and healthcare policy.

Click here to access the The Burden of Musculoskeletal Disease in the United States.